Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

03 November 1997

Coronary stent implantation results in patients treated with ticlopidine and aspirin

Maciej Kośmider

Med Sci Monit 1997; 3(6): CR821-825 :: ID: 501788

Abstract

Antiplatelet drugs gradually replace anticoagulants in patients subjected to coronary artery stenting. The purpose of this paper is to present our own experiences associated with combined treatment with ticlopidine and aspirin. From June 1995 until December 1996 118 patients were subjected to placement of 127 coronary stents in our laboratory (including 58 PS, 52 GR II, 11 Wiktor and 6 NIR stents). The procedure was performed in planned course in 101 patients, while in 17 patients - in situation threatening of sudden occlusion of coronary artery (bail-out) or in its factual occurrence. All patients were treated with 10 000 IU of heparin IV, Aspirin 250 mg/day PO and Ticlopidine 2i250 mg. If the stent implantation was a planned course procedure, ticlopidine had been started three days before. If the decision was made during the angioplasty, the patient was treated with 500 mg during the procedure of stent placement. The drug was administered for 30 days unless side effects occurred. PS 153 and NIR stents were distended under high pressure of 16-18 Atm, Wiktor and GR II of 8-13 atm. No systematic ICUS control was conducted. None of the patients who had successful stent implantation had haemorrhagic complications or thrombosis symptoms. During 8-month follow-up period clinical symptoms of restenosis occurred in 10 cases, out of which 7 in the stent and 3 before or after it, as diagnosed on a control coronarography. Conclusion: Ticlopidine and Aspirin combined treatment provides good immediate and long term effect in coronary stent implantation, irrespective of the course of the procedure.

Keywords: Angioplasty, coronary stent implantation, antiplatelet treatment

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750